ICAM-1 Assay Portfolio Service

Changes in the expression of CAMs occur in tumorigenesis and its progression. Intercellular adhesion molecule-1 (ICAM-1) is expressed on the surface of those cells which are intimately involved in inflammatory reactions and progression of tumor and it becomes a potential molecular target and biomarker for TNBC therapy and diagnosis. With advanced and high-end technologies, rich experienced scientists, Creative Biolabs is an excellent service provider in the field of tumor marker assay. After long years ahead to fully comprehend tumor marker, we launch our ICAM-1 assay portfolio service which can be useful for targeted cancer therapy and diagnosis.

Introduction of ICAM-1

ICAM-1, also known as CD106, is a cell surface glycoprotein belonging to the member of the immunoglobulin superfamily. ICAM-1 is expressed in several cell types, including vascular endothelial cells and on some lymphocytes and monocytes, macrophages, B- and T-lymphocytes, fibroblasts and epithelial cells.

ICAM-1 plays a crucial role in inflammatory conditions, nervous system development, immune responses through antigen recognition and lymphocyte circulation and activation. Except for the role in immune responses, it has also been related to tumor progression and prognosis in multiple types of cancer, such as breast cancer, gastrointestinal cancer and melanoma.

ICAM-1 Mediated Pathways

• The ligation of ICAM-1 in LSECs triggers the secretion of IL-1β and sICAM-1 concomitant to the upregulation of ManR, leading to a decrease in the cytotoxic potential of LSLs.
• The activation of tumor cells by ICAM-1 secretes VEGF and PGE2 facilitating the recruitment of MDSCs, LSECs and HSCs leading to angiogenesis.
• The interaction between HSCs and lymphocyte ICAM-1 blocks lymphocyte-mediated tumor clearance.
• The upregulation of ICAM-1 expression in LSECs leads to the MDSCs infiltrating the liver, which impedes the antitumor response of infiltrating and resident lymphocytes is impeded.
• The ligation of ICAM-1 in stromal cells drives to TNF-α, and IL-6 release, amplifying the effect on tumor progression.

Fig.1 ICAM-1 mediated protumoral pathways. (Benedicto, 2017)

Role of ICAM-1 in Tumors

• Inhibiting tumor growth and metastasis by transfecting ICAM-1 into colorectal cancer cell lines.
• Reducing the cytotoxic effectivity of T cells by limiting the expression of ICAM-1 in tumor cells.
• Expression of ICAM-1 has been positively correlated with a more aggressive tumor phenotype and metastatic potential. For example, the invasiveness of breast cancer cells has been positively correlated with the expression of ICAM-1.
• Overexpression of ICAM-1 was shown in tumor-associated fibroblasts in colorectal cancer tissue sections compared to healthy mucosa.

ICAM-1 Blockade Assays at Creative Biolabs include but Not Limited to:

• Invasion assay
• Proliferation assay
• Metastasis assay
• Migration assay
• Cytokine assay
• Cytotoxicity assay
• Angiogenesis assay

If you are interested in our service, please contact us or directly send us.

References

• Benedicto, A.; et al. Role of liver ICAM-1 in metastasis. Oncol Lett. 2017, 14(4): 3883-3892.
• Kotteas, E.A.; et al. The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: implications for disease progression and prognosis. Anticancer Res. 2014, 34(9): 4665-72.

For Research Use Only | Not For Clinical Use